Omnicell delivers strong fourth quarter financial results. Results exceed previously issued full year guidance for bookings, total revenues, and non-GAAP EBITDA. FORT WORTH, Texas ...

Omnicell OMCL is advancing toward the industry-defined vision of Autonomous Pharmacy by leveraging automation and advanced services across its cloud-based platform. The strength of the company’s ...

Benchmark analysts maintained a Buy rating on Omnicell stock (NASDAQ:OMCL) with a consistent price target of $62.00 as the company approaches its earnings release scheduled for February 6. The target ...

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the fourth quarter ...

who will share first-hand experiences of how technology and professional services are enhancing operational and clinical outcomes in both IV compounding and specialty pharmacy. To learn more about ...

The market expects Omnicell (OMCL) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and ...

Analyst Allen Lutz of Bank of America Securities maintained a Hold rating on Omnicell (OMCL – Research Report), retaining the price target of $46.00. Allen Lutz has given his Hold rating due to ...

Omnicell expects expansion as customers increase the use of its dispensing systems in more areas within their hospitals and ambulatory care settings. The Central Pharmacy and IV Compounding market ...

Omnicell OMCL is advancing toward the industry-defined vision of Autonomous Pharmacy by leveraging automation and advanced services across its cloud-based platform. The strength of the company’s ...